- Acceleron leaders and Westlake jumpstart new IPF biotechAfter success with the drug Winrevair, a band of entrepreneurs has found their next challenge in a difficult-to-treat lung disease. On Tuesday, Oorja Bio launched with a $30 million Series A round,…Endpoints · 2mo ago↗ source
- BioMarin drug acquired in buyout misses goal in rare disease studyTested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.BioPharma Dive · 2mo ago↗ source
- The state of consumer healthOn Thursday, the Health Tech team led a series of conversations at the Financial Times’ US Pharma and Biotech Summit, held in collaboration with Endpoints News. The sessions focused on ...Endpoints